[{"orgOrder":0,"company":"Microbion","sponsor":"CARB-X","pharmaFlowCategory":"D","amount":"$17.1 million","upfrontCash":"Undisclosed","newsHeadline":"Microbion Gets $17.1 M from CARB-X and Cystic Fibrosis Foundation to Develop Inhaled Antimicrobial for Chronic Respiratory Infections in CF","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Funding","leadProduct":"Pravibismane","moa":"","url1":"","url2":"","graph1":"Podiatry","graph2":"Phase II","graph3":"Microbion","amount2":0.02,"therapeuticAreaNew":"Podiatry","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Podiatry","productSubType":"Small molecule","amount2New":0.02,"dosageForm":"","sponsorNew":"Microbion \/ CARB-X","highestDevelopmentStatusID":"8","companyTruncated":"Microbion \/ CARB-X"},{"orgOrder":0,"company":"MediWound","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MediWound Enrolls First Patient in Phase 2 Pharmacology Study of EscharEx","therapeuticArea":"Podiatry","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Proteolytic enzymes enriched in bromelain","moa":"Peptide hydrolase","url1":"","url2":"","graph1":"Podiatry","graph2":"Phase II","graph3":"MediWound","amount2":0,"therapeuticAreaNew":"Podiatry","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Podiatry","productSubType":"","amount2New":0,"dosageForm":"Topical gel","sponsorNew":"MediWound \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"MediWound \/ Not Applicable"},{"orgOrder":0,"company":"MediWound","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MediWound Completes Patient Enrollment for Interim Assessment of its U.S. EscharEx Phase 2 Adaptive Design Study","therapeuticArea":"Podiatry","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Proteolytic Enzymes Enriched in Bromelain","moa":"Peptide hydrolase","url1":"","url2":"","graph1":"Podiatry","graph2":"Phase II","graph3":"MediWound","amount2":0,"therapeuticAreaNew":"Podiatry","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Podiatry","productSubType":"","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"MediWound \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"MediWound \/ Not Applicable"},{"orgOrder":0,"company":"MediWound","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MediWound Announces Positive Outcome of Interim Assessment for its EscharEx U.S. Phase 2 Adaptive Design Study","therapeuticArea":"Podiatry","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Proteolytic Enzymes Enriched in Bromelain","moa":"Peptide hydrolase","url1":"","url2":"","graph1":"Podiatry","graph2":"Phase II","graph3":"MediWound","amount2":0,"therapeuticAreaNew":"Podiatry","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Podiatry","productSubType":"","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"MediWound \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"MediWound \/ Not Applicable"},{"orgOrder":0,"company":"MediWound","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MediWound Completes Enrollment of its EscharEx U.S. Phase 2 Adaptive Design Study","therapeuticArea":"Podiatry","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Proteolytic Enzymes Enriched In Bromelain","moa":"Peptide hydrolase","url1":"","url2":"","graph1":"Podiatry","graph2":"Phase II","graph3":"MediWound","amount2":0,"therapeuticAreaNew":"Podiatry","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Podiatry","productSubType":"","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"MediWound \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"MediWound \/ Not Applicable"},{"orgOrder":0,"company":"Lakewood-Amedex","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lakewood-Amedex Enrolls First Patient in Phase 2 Clinical Trial for Patients with Chronic Diabetic Foot Ulcers (cDFU)","therapeuticArea":"Podiatry","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Bisphosphocin","moa":"Cell membrane","url1":"","url2":"","graph1":"Podiatry","graph2":"Phase II","graph3":"Lakewood-Amedex","amount2":0,"therapeuticAreaNew":"Podiatry","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Podiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Lakewood-Amedex \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Lakewood-Amedex \/ Not Applicable"},{"orgOrder":0,"company":"MediWound","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MediWound Announces Positive Results from its U.S. Phase 2 Pharmacology Study of EscharEx for Debridement of Lower Leg Ulcers","therapeuticArea":"Podiatry","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Bromelain Enriched Proteolytic Enzyme","moa":"Peptide hydrolase","url1":"","url2":"","graph1":"Podiatry","graph2":"Phase II","graph3":"MediWound","amount2":0,"therapeuticAreaNew":"Podiatry","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Podiatry","productSubType":"","amount2New":0,"dosageForm":"Gel","sponsorNew":"MediWound \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"MediWound \/ Not Applicable"},{"orgOrder":0,"company":"Promore Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Promore Pharma Granted EU Patent Regarding Treatment of Chronic Wounds","therapeuticArea":"Podiatry","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Ropocamptide","moa":"Keratinocyte","url1":"","url2":"","graph1":"Podiatry","graph2":"Phase II","graph3":"Promore Pharma","amount2":0,"therapeuticAreaNew":"Podiatry","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Podiatry","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Promore Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Promore Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Microbion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Microbion Corporation Initiates Phase 2 Clinical Study Evaluating Topical Pravibismane Treatment of Diabetic Foot Infections","therapeuticArea":"Podiatry","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Pravibismane","moa":"","url1":"","url2":"","graph1":"Podiatry","graph2":"Phase II","graph3":"Microbion","amount2":0,"therapeuticAreaNew":"Podiatry","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Podiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Microbion \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Microbion \/ Not Applicable"},{"orgOrder":0,"company":"MediWound","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MediWound Receives Positive Scientific Advice from European Medicine Agency (EMA) on EscharEx Phase III Study Design","therapeuticArea":"Podiatry","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"EX-02","moa":"","url1":"","url2":"","graph1":"Podiatry","graph2":"Phase II","graph3":"MediWound","amount2":0,"therapeuticAreaNew":"Podiatry","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Podiatry","productSubType":"","amount2New":0,"dosageForm":"Gel","sponsorNew":"MediWound \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"MediWound \/ Not Applicable"},{"orgOrder":0,"company":"Molnlycke Health Care AB","sponsor":"MediWound","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"MediWound Announces Collaboration with M\u00f6lnlycke on EscharEx\u00ae Phase III Study","therapeuticArea":"Podiatry","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Collaboration","leadProduct":"EX-02","moa":"","url1":"","url2":"","graph1":"Podiatry","graph2":"Phase II","graph3":"Molnlycke Health Care AB","amount2":0,"therapeuticAreaNew":"Podiatry","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Podiatry","productSubType":"","amount2New":0,"dosageForm":"Gel","sponsorNew":"Molnlycke Health Care AB \/ MediWound","highestDevelopmentStatusID":"8","companyTruncated":"Molnlycke Health Care AB \/ MediWound"},{"orgOrder":0,"company":"3M Health Care","sponsor":"MediWound","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"MediWound Announces Collaboration with 3M on EscharEx\u00ae Phase III Study","therapeuticArea":"Podiatry","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Collaboration","leadProduct":"EX-02","moa":"","url1":"","url2":"","graph1":"Podiatry","graph2":"Phase II","graph3":"3M Health Care","amount2":0,"therapeuticAreaNew":"Podiatry","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Podiatry","productSubType":"","amount2New":0,"dosageForm":"Gel","sponsorNew":"3M Health Care \/ MediWound","highestDevelopmentStatusID":"8","companyTruncated":"3M Health Care \/ MediWound"},{"orgOrder":0,"company":"MediWound","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MediWound Announces Positive Topline Results from its U.S. Phase 2 Trial of EscharEx for Debridement of Chronic Wounds","therapeuticArea":"Podiatry","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"Bromelain Enriched Proteolytic Enzyme","moa":"","url1":"","url2":"","graph1":"Podiatry","graph2":"Phase II","graph3":"MediWound","amount2":0,"therapeuticAreaNew":"Podiatry","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Podiatry","productSubType":"","amount2New":0,"dosageForm":"Gel","sponsorNew":"MediWound \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"MediWound \/ Not Applicable"},{"orgOrder":0,"company":"Discovery Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Discovery Therapeutics Caribe Receives Study May Proceed Letter from FDA to Initiate a Phase 3 Clinical Trial of Intralesional rhEGF for the Treatment of Diabetic Foot Ulcers","therapeuticArea":"Podiatry","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"Approved","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Recombinant Human Epidermal Growth Factor","moa":"","url1":"","url2":"","graph1":"Podiatry","graph2":"Phase II","graph3":"Discovery Therapeutics","amount2":0,"therapeuticAreaNew":"Podiatry","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Podiatry","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Discovery Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Discovery Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Rion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"RION Announces First Patient Dosed in Phase 2 Clinical Study of Purified Exosome Product\u2122 for Diabetic Foot Ulcers","therapeuticArea":"Podiatry","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Purified Exosome-based Therapy","moa":"","url1":"","url2":"","graph1":"Podiatry","graph2":"Phase II","graph3":"Rion","amount2":0,"therapeuticAreaNew":"Podiatry","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Podiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Rion \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Rion \/ Not Applicable"}]